Viatris Inc

Health Care
Biotechnology: Pharmaceutical Preparations
www.viatris.com

Earnings Score
Moat Score
Safety Score

Market Cap $15.18B
PE -17
Debt $15.75B
Cash $1.88B
EV $29.05B
FCF $1.95B

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$883.30M
EBIT	-$264.60M
ROE	-4%
ROA	-1%
FCF	$1.95B
Equity	$19.79B
Growth Stability	100%
PE	-17.18
PEG	-1.45
PB	0.77
P/FCF	7.79
P/S	1.01
Price/Cash	0.12
Debt/Equity	0.8
Debt/FCF	8.08
Net Margins	-1%
Gross Margins	40%
Op. Margins	-2%
Earnings CAGR	10%
Sales Growth YoY	-5%
Sales Growth QoQ	-1%
Sales CAGR	20%
FCF CAGR	4%
Equity CAGR	9%
Earnings Stability	-0.38
Earnings Growth YoY	-71%
Earnings Growth QoQ	-129%
Earnings CAGR 5Y	12%

Sales CAGR 5Y	21%
FCF CAGR 5Y	9%
Equity CAGR 5Y	6%
Earnings CAGR 3Y	-6%
Sales CAGR 3Y	-6%
FCF CAGR 3Y	-14%
Equity CAGR 3Y	-1%
Market Cap	$15.18B
Revenue	$15.05B
Dividend Yield	4%
Payout Ratio	-67%
Assets	$44.75B
Total Debt	$15.75B
Cash	$1.88B
Shares Outstanding	1.19B
EV	29.05B
Earnings Score	6%
Moat Score	16%
Safety Score	79%
Final Score	34%
Working Capital	3.8B
Current Ratio	1.51
Gross Profit	$6.01B
Shares Growth 3y	-1%
Equity Growth QoQ	1%
Equity Growth YoY	-5%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

We are Viatris. A new kind of global healthcare company empowering people worldwide to live healthier at every stage of life. We provide access to medicines advance sustainable operations develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway. Formed in November 2020 we bring together scientific manufacturing and distribution expertise with proven regulatory medical and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. At Viatris our portfolio comprises more than 1400 approved molecules across a wide range of therapeutic areas spanning both non-communicable and infectious diseases including globally recognized brands complex generic and branded medicines and a growing portfolio of biosimilars.

SEC Filings

Direct access to Viatris Inc (VTRS) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Viatris Inc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Viatris Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 10%

Stability -38%

loading chart...

Viatris Inc Discounted Cash Flow

Fully customizable DCF calculator online for Viatris Inc.

Years

Calculation mode

= $26B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$1.9B	$2B	$2.1B	$2.2B	$2.3B	$2.4B	$2.5B	$2.6B	$2.7B	$2.8B	$3B	$30B
DCF		$1.8B	$1.8B	$1.7B	$1.6B	$1.5B	$1.4B	$1.3B	$1.3B	$1.2B	$1.1B	$11B
Value	$26B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	3%	0%	-6%	-7%	13%	0%	-1%
ROA	-	-	-0%	-0%	6%	2%	-1%
ROE	-	0%	-3%	-6%	10%	0%	-4%

Bad Net Margins (-1.05%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-7.07	-	8.92	7.84	8.07	8.08
Debt over Equity	-	0.13	1.14	1.11	0.95	0.96	0.8
Growth Stability	-	-	-	-	-	100%	100%

Bad Debt/FCF ratio (8.08)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Good Debt/Equity ratio (0.8)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (100%)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	1%	4%	50%	-9%	-5%	21%
Earnings YoY growth	-	-100%	-	89%	-264%	-97%	12%
Equity YoY growth	-	-2%	93%	-11%	3%	-3%	6%
FCF YoY growth	-	-110%	-564%	159%	-1%	-5%	9%